Skip to main content

Year: 2024

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today...

Continue reading

Kornit Digital Reports Third Quarter 2024 Results

Third quarter revenues of $50.7 million, in line with previous guidance Third quarter GAAP net loss of $0.9 million; non-GAAP net income of $5.5 million Continued positive cash generation from operations Significant year-over-year improvement in non-GAAP gross margin and return to adjusted EBITDA profitability Industry-leading platforms, Apollo and Atlas MAX, continue to gain adoption among screen-replacement customers, driven by the new AIC modelROSH-HA`AYIN, Israel, Nov. 06, 2024 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production technologies, today reported results for the third quarter ended September 30, 2024. “I am very pleased with the operational progress we achieved this quarter. We delivered gross margin...

Continue reading

Orion Reports Q2’25 Results with Revenue of $19.4M, Reflecting 40% Growth in EV Charging and Significant Improvement in Maintenance Segment Gross Margin

MANITOWOC, Wis., Nov. 06, 2024 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today reported results for its fiscal 2025 second quarter (Q2’25) ended September 30, 2024. Orion will hold an investor call today at 10:00 a.m. ET – details below.Q2 Financial Summary   Prior Three Quarters$ in millions except per share figures Q2’25 Q2’24 Change   Q1’25 Q4’24 Q3’24LED Lighting Revenue $10.8 $13.6 -20%   $12.8 $16.3 $18.5EV Charging Revenue $4.7 $3.4 40%   $3.8 $4.9 $2.8Maintenance Revenue $3.8 $3.6 5%   $3.3 $5.2 $4.6Total Revenue $19.4 $20.6 $(1.2)   $19.9 $26.4 $26.0Gross Profit (1) $4.5 $4.6 $(0.1)   $4.3 $6.8 $6.4Gross Profit...

Continue reading

Royalty Pharma Reports Third Quarter 2024 Results

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15% Net cash provided by operating activities of $704 million Capital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 millionNEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. “We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We also strengthened our portfolio by adding royalties on three innovative therapies over the last three months, increasing our Capital...

Continue reading

Vertex Announces Third Quarter 2024 Financial Results

KING OF PRUSSIA, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2024. “The third quarter of 2024 was another great quarter for Vertex”, stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “Revenue was above the high end of our quarterly guidance, with mid-teens organic revenue growth. We were once again GAAP earnings positive with strong Adjusted EBITDA. And we delivered significant cash flow from operating activities as well as free cash flow, demonstrating our high-quality earnings.” DeStefano continued, “In the third quarter we completed our acquisition of Austrian e-invoicing and EDI company, ecosio. We are...

Continue reading

Avista Corp. Reports Financial Results for the Third Quarter of 2024

Quarterly results demonstrate continued improvement at core utility from 2023 Expect to be at the low end of Avista Utilities guidance range Lowering earnings guidance for our other businesses due to lower than expected investment valuationsSPOKANE, Wash., Nov. 06, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the third quarter of 2024. Net income and earnings per diluted share for the third quarter and year-to-date 2024 compared to the same periods in 2023 are presented in the table below (dollars in thousands, except per-share data):    Third Quarter     Year-to-Date      2024     2023     2024     2023  Net Income (Loss) by Business Segment:                        Avista Utilities   $ 19,803     $ 13,498     $ 111,246     $ 83,935  AEL&P     41       288       5,061       5,689  Other     (1,357 )     930       (3,467 )     (2,579 )Total...

Continue reading

Vishay Intertechnology Reports Third Quarter 2024 Results

MALVERN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal third quarter ended September 28, 2024. Highlights3Q 2024 revenues of $735.4 million Gross margin was 20.5% and included the negative impact of approximately 150 basis points related to the addition of Newport GAAP loss per share of ($0.14); adjusted EPS of $0.08 per share 3Q 2024 book-to-bill of 0.88 with book-to-bill of 0.79 for semiconductors and 0.97 for passive components Backlog at quarter end was 4.4 months“For the third consecutive quarter this year, revenue has held fairly constant, reflecting a prolonged period of inventory de-stocking as the pace of consumption by industrial customers...

Continue reading

Astec Reports Third Quarter 2024 Results

Third Quarter 2024 Overview (all comparisons are made to the corresponding prior year third quarter unless otherwise specified):Net sales of $291.4 million decreased 3.9% Net loss of $6.2 million, which included an $8.4 million charge related to the settlement of a legacy litigation matter: Adjusted net income of $7.0 million EBITDA of $0.6 million declined $1.2 million; Adjusted EBITDA was $17.4 million, an increase of $7.4 million Diluted EPS of $(0.27) compared to $(0.29); Adjusted EPS of $0.31 compared to $(0.01) Operating cash flow of $22.5 million; Free cash flow of $19.9 millionCHATTANOOGA, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced today its financial results for the third quarter ended September 30, 2024. “In the third quarter, we had mixed results. In Infrastructure...

Continue reading

Immunocore reports third quarter financial results and provides a business update

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 06 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and...

Continue reading

Brookfield Infrastructure Achieves Capital Recycling Target and Announces Third Quarter 2024 Results

BROOKFIELD, News, Nov. 06, 2024 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (Brookfield Infrastructure, BIP, or the Partnership) (NYSE: BIP; TSX: BIP.UN) today announced its results for the third quarter ended September 30, 2024. “Brookfield Infrastructure continues to deliver solid results while achieving its strategic objectives, including successfully reaching our $2 billion capital recycling target for the year,” said Sam Pollock, Chief Executive Officer of Brookfield Infrastructure Partners. “With interest rates coming down, we are in a new market environment with increased deal flow, creating a significant investment pipeline that is also benefiting from growth in sectors related to AI and associated energy demands.”  For the three months ended September 30   For the nine months ended September 30US$...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.